GeneDx Holdings Corp

GeneDx insider trades reveal cautious optimism: CEO RSU swaps, CFO purchases, and AI‑driven rare‑disease diagnostics amid regulatory shifts and market uncertainty.

GeneDx insider selling spurs investor scrutiny: COO Dechairo Bryan cuts stake, raising questions on AI‑driven genomics growth and liquidity.

GeneDx insider trades show COO’s confidence in AI‑driven diagnostics, aligning executive incentives with shareholder value and reflecting strategic growth in genomic healthcare.